Clinical Trial Update: Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS) [Phase 2]

View source ↗

Summary

Phase 2 trial update for RETAIN-MS evaluating atomoxetine treatment in memory disorders associated with multiple sclerosis; study completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Memory Disorders
• Multiple Sclerosis

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Memory Disorders, Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2020-03-13